Anti-VEGF Receptor 2 抗体, prediluted (ab15292)

製品の概要

  • 製品名Anti-VEGF Receptor 2 antibody, prediluted
    VEGF Receptor 2 一次抗体 製品一覧
  • 製品の詳細
    Rabbit polyclonal to VEGF Receptor 2, prediluted
  • アプリケーション適用あり: IHC-Pmore details
  • 種交差性
    交差種: Human
    交差が予測される動物種: Mouse, Rat
  • 免疫原

    Synthetic peptide (unfortunately, the amino acid sequence is considered to be commercially sensitive) (Human) (C terminal).

  • ポジティブ・コントロール
    • Angiosarcoma

アプリケーション

Our Abpromise guarantee covers the use of ab15292 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

アプリケーション Abreviews 特記事項
IHC-P
  • 追加情報IHC-P: Ready to use. Polyvalent-HRP-AEC detection system (biotin-streptavidin amplification system) is necessary. Perform heat-mediated antigen retrieval before commencing with IHC staining protocol, by boiling tissue sections in 10mM citrate buffer, pH 6.0 for 10 min followed by cooling at RT for 20 min.

    Not tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • ターゲット情報

    • 機能Receptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.
    • 関連疾患Defects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma.
    • 配列類似性Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
      Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
      Contains 1 protein kinase domain.
    • 翻訳後修飾Phosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214.
    • 細胞内局在Membrane.
    • Information by UniProt
    • 参照データベース
    • 別名
      • CD309 antibody
      • CD309 antigen antibody
      • EC 2.7.10.1 antibody
      • Fetal liver kinase 1 antibody
      • FLK-1 antibody
      • FLK1 antibody
      • FLK1, mouse, homolog of antibody
      • Kdr antibody
      • Kinase insert domain receptor (a type III receptor tyrosine kinase) antibody
      • Kinase insert domain receptor antibody
      • KRD1 antibody
      • Ly73 antibody
      • Protein tyrosine kinase receptor FLK1 antibody
      • Protein-tyrosine kinase receptor flk-1 antibody
      • soluble VEGFR2 antibody
      • Tyrosine kinase growth factor receptor antibody
      • Vascular endothelial growth factor receptor 2 antibody
      • VEGFR 2 antibody
      • VEGFR antibody
      • VEGFR-2 antibody
      • VEGFR2 antibody
      • VGFR2_HUMAN antibody
      see all

    Anti-VEGF Receptor 2 antibody, prediluted 画像

    • ab15292, staining VEGF receptor 2 in human placenta by Immunohistochemistry (FFPE-sections).

    Anti-VEGF Receptor 2 antibody, prediluted (ab15292) 使用論文

    ab15292 has not yet been referenced specifically in any publications.

    Product Wall

    I have just received the following information from the originator of ab15292:ab15292 was optimised with polyvalent-HRP-AEC detection system (biotin-streptavidin system). The originator suggests that that the detection system you are currently using ...

    Read More

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"